23 February, 2014

Introducing The Rowboat
A advanced Covered Call system that is quite possib
ly The Holy Grail of
Investing.
Step 1 : Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per contract if
the option is exercised, this is also my maximum risk. )
INSM Insmed Incorporated
Sell To Open INSM March
2014 $15.00 Put @ Market
Currently $1.50 bid / $1.63 time
10%
return in 25 days
$10,000 should generate
$1000.00
How to do this trade and commentary Video:

Sign up with a auto-trading company and let your broker do the trades for
you. Insmed Incorporated, a biopharmaceutical company, focuses on developing and
commercializing targeted inhalation therapies for patients battling serious lung
diseases. Its lead candi date ARIKACE is engineered to deliver a proven and
potent anti-infective directly to the site of serious lung infections to improve the
treatment for two identified patient populations comprising cystic fibrosis (CF)
patients with Pseudomonas aeuruginosa lung infections and patients with
nontuberculous mycobacteria lung infections (NTM). The companys hase III
registrational study of ARIKACE in CF patients in Europe and Canada has
completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

Insmed Incorporated 9 Deer Park Drive Suite CMonmouth Junction, NJ 08852
Phone: 732-997-4600
Website: http://www.insmed.com
QCOR @ $76.51
Questcor Pharmaceuticals, Inc. Sell To Open QCOR March 2014 $70 Put @ Market
Currently $4.00 bid / $4.25 time 5.71% return in 25 days
$10,000 should generate $571.00 How to do this trade and comm – E9Dg
*same video as last month just a different price point
Sign up with a auto – trading company and let your broker do the trades for
you. Questcor Pharmaceuti
cals, Inc., a biopharmaceutical company, provides drugs
for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms
indications. It primarily offers H.P. Acthar Gel, an injectable drug for the
treatment of acute exacerbations of multi
ple sclerosis in adults; to induce a
diuresis or a remission of proteinuria in the nephrotic syndrome without uremia
of the idiopathic type or that due to lupus erythematosus; and as monotherapy
for the treatment of infantile spasms in infants and children
under two years of
age. The companys .P. Acthar Gel also focuses on rheumatology

related
conditions, including collagen diseases and rheumatic disorders. In addition, it
offers Doral for the treatment of insomnia. The company sells its Acthar
primarily
to specialty pharmacies; and Doral to pharmaceutical wholesalers.
Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in
Anaheim, California.
Questcor Pharmaceuticals, Inc.
1300 North Kellogg Drive
Suite D
Anaheim, CA 92807
Phone: 714

786

4200
Fax: 714

789

4229
Website:
http://www.questcor.com

News:
SCTY
@ $75.86
solar city corporation
Sell To Open SCTY March 2014 $75.00 Put @ Market
currently $6.40 bid / $6.50 time
8.5%
return in 25 da
ys
$10,000 should generate
$850.00
How to do this trade and commentary Video:

*same video as last month
Sign up with a auto

trading company and let your broker do t
he trades for
you.
SolarCity Corporation engages in the design, installation, and sale or
lease of solar energy systems to residential and commercial customers,
and government entities in the United States. It provides solar energy
systems; and energy e
fficiency products and services, including home
energy evaluation, and energy efficiency upgrade products and services.
The company also sells electricity generated by solar energy systems to
customers. In addition, it markets and installs electric vehicle
charging
equipment to residential and commercial customers through retail
partnerships. The company was founded in 2006 and is headquartered in
San Mateo, California.
SolarCity Corporation
3055 Clearview Way
San Mateo, CA 94402
Phone: 650

638

1028
Fax
: 650

638

1029
Website:
http://www.solarcity.com
News:

Remember, no more than 5 or 10% of your portfolio should ever go into
any one trade or position.
Step 2:
IF
it got Put to us,
Now
we
“Lock

in” a profit.
Sell
the
Covered Call
(Do not buy a stock just to sell the covered Call)
Nothing got Put to us.
Remember, no more than 5 or 10% of your portfolio should ever go into
any one trade or position.

How did we do last Month?
Expired Puts
VNDA
@$13.94
V
anda Pharmaceuticals, Inc.
4.5%
return
Strategy: Sold Puts
01/21/2014 Sell To Open VNDA Feb14 $10 Put $0.45

4.5%
return in 25 days
$10,000 should generate
$450.00
QCOR
@ $76.51
Questcor Pharmaceuticals, Inc.
3.48%
return
Strategy: Sold Puts
01/21/2014 Sell To Open QCOR Feb14 $57.5 Put $2.00
3.48%
return in 25 days
$10,000 would have generated
$348.00
SCTY
@ $75.86
solar city corporation
9.2%
return
Strategy: Sold Puts
01/21/2014 Sell To Open SCTY Feb14 $75 Put $6.90
9.2%
return in 25 d
ays
$10,000 would have generated
$920.00
MYGN
@ $37.36
Myriad Genetics Inc. (MYGN)
Called away
Move to closed positions
History:
Cost basis
$25.00
per share.
Capital Gain:
$2.00
Premiums collected:
$3.10
per share
20.4%
Return in 3 months
$10,000
would have generated
$2040.00

02/21/2014 Sell
MYGN Stock Assignment
$27.00
01/21/2014 Sell To Open MYGN Feb14 $27 Call $0.35
12/23/2013 Sell To Open MYGN Jan14 $27 Call $0.85
12/20/2013 Buy MYGN

Stock Assignment
$25.00
11/18/2013 Sell To Open MYGN Dec13
$25 Put $1.90
Current/Older Positions/History
This includes a running total for each open position.
Do not enter these positions.
CLSN
@ $3.62
Celsion Corporation
Put to us @ $2.00
Sell To Open CLSN March 2014 $4 Call @ Market
currently .10 bid
/ .13 time
History:
Cost basis
$2.00
per share.
Premiums collected:
$1,15
per share
57.5%*
Return in 14 months
*
This does not factor in any stock split.
$10,000 would have generated $4500.00
actual trades:
01/21/2014 Sell To Open
CLSN Feb14 $4 C
all $0.25
12/23/2013 Sell To Open CLSN Jan14 $4 Call $0.15
11/18/2013 Sell To Open CLSN Dec13 $4 Call $0.25
02/19/2013 Sell To Open CLSN July 2013 $3 Call
(did not fill, because of Holiday) 0.00
02/15/2013 Buy CLSN

Option Assignment $2.00
01/22/2013 Se
ll To Open CLSN Feb13 $2 Put $0.30
12/24/2012 Sell To Open CLSN Jan13 $2 Put $0.20
Celsion Corporation, an oncology drug development company, engages in the
development and commercialization of targeted chemotherapeutic oncology
drugs based on its propr
ietary heat

activated liposomal technology. The company
develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under
Phase III clinical trial for primary liver cancer; under phase II clinical trial for
colorectal liver metastasis; and under
phase II clinical trial for treatment of
recurrent chest wall breast cancer. It has a development, product supply, and

commercialization agreement with Yakult Honsha Co. for ThermoDox; a license
agreement with Duke University to commercialize and use Duke
‘s thermo

liposome technology; and a joint research agreement with Royal Philips
Electronics to evaluate the combination of Philips’ high intensity focused
ultrasound with its ThermoDox to determine the potential of this combination to
treat various cancer
s. The company was founded in 1982 and is based in
Lawrenceville, New Jersey.
Celsion Corp.
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
Phone: 609

896

9100
Fax: 609

896

2200
Website:
http://www.celsion.com
News:
DMND
@ $27.58
Put to us @ $32.00
Hold
June 2014 $33 Call is still cooking
7.9
%
Return
History:
Cost basis
$32.00
per share.
Premiums collected:
2.55
per share
7.9%
Return in 24 months
$10,000 would have generated
$790.00
actual trade
s:
01/21/2014 Sell To Open DMND Jun14 33 Call $0.40
09/24/2012 Sell To Open DMND Dec12 30 Call $0.20
03/20/2012 Sell To Open DMND Jun12 33 Call $0.25
03/18/2012 Buy To Close EXPIRED DMND Mar12 32 CALL
02/21/2012 Sell To Open DMND Mar12 32 Call $0.20
02
/17/2012 Buy DMND

Option Assignment $32.00
02/17/2012 Buy To Close DMND Feb12 32 Put
02/06/2012 Sell To Open DMND Feb12 32 Put $1.50

Diamond Foods, Inc. engages in processing, marketing, and distributing snack products.
It provides snack products, in
cluding roasted, glazed and flavored nuts, trail mixes, dried
fruit, seeds, microwave popcorn products, and potato and tortilla chips under the
Emerald, Pop Secret, and Kettle brands. The company also offers culinary, in

shell, and
ingredient nuts under th
e Diamond of California brand name. It markets its culinary nuts
to individuals who prepare meals or baked goods at home; and ingredient nuts to food
processors, restaurants, bakeries, and food service companies and their suppliers. The
company sells its p
roducts directly to national grocery, mass merchandiser, clubs,
convenience stores, and drug store chains in the United States, the United Kingdom,
Germany, the Netherlands, Spain, Canada, South Korea, Turkey, China, and Japan.
Diamond Foods, Inc. was foun
ded in 1912 and is based in San Francisco, California.
Diamond Foods, Inc.
600 Montgomery Street
13th Floor
San Francisco, CA 94111

2702
Phone: 415

445

7444
Website:
http://www.diamondfoods.com
News:
http://www.fool.com/investing/general/2013/12/09/inside-diamond-foods-shame-and-3-key-takeaways-fro.aspx#.UrXUHvtyX3g

MYGN
@ $37.36
Myriad Genetics Inc. (MYGN)
Called away
Move to closed positions
History:
Cost basis
$25.00
per share.
Capital Gain:
$2.00
Premiums collected:
$3.10
per share
Total
$5.10
20.4%
Return in 3 months
$10,000 would have generated
$2040.00
actual trades:
02/21/2014 Sell
MYGN Stock Assignment
$27.00
01/21/2014 Sell To Open MYGN Feb14 $27 Call $0.35
12/23/2013 Sell To Open MYGN Jan14 $27 Call $0.85
12/20/2013 Buy MYGN

Stock Assignment
$25.00
11/18/2013 Sell To Open MYGN Dec13 $25
Put $1.90
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the
development and marketing of predictive medicine, personalized
medicine, and prognostic medicine tests primarily in the United States.
The company’s molecular diagnostic tests
are designed to analyze
genes, their mutations, expression levels, and proteins to assess an

individuals risk for developing disease
later in life; determine a patients
likelihood of responding to a particular drug; and assess a patients risk of
disease p
rogression and disease recurrence. It offers various molecular
diagnostic tests that include BRACAnalysis and BART, which are
predictive medicine tests for hereditary breast and ovarian cancer;
COLARIS predictive medicine test for hereditary colorectal and
uterine
cancer; COLARIS AP predictive medicine test for hereditary colorectal
cancer; MELARIS predictive medicine test for hereditary melanoma;
PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a
personalized and prognostic medicine test
for cancer; Prolaris, a
prognostic medicine test for prostate cancer; and TheraGuide 5

FU, a
personalized medicine test for drug toxicity. The company, through its
subsidiary, Myriad RBM, Inc., also offers biomarker discovery and
companion diagnostic serv
ices to the pharmaceutical, biotechnology, and
medical research industries that include multi

analyte profile testing
services; multiplexed immunoassay kits; and TruCulture, a self

contained
whole blood culture that allows pharmaceutical and biotechnology
companies to identify drug toxicity prior to human trials. Myriad Genetics,
Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics Inc.
320 Wakara Way
Salt Lake City, UT 84108
Phone: 801

584

3600
Fax: 801

584

3640
Website:
http://www.myriad.com
News:
http://finance.yahoo.com/news/myriad-myrisk-hereditary-cancer-tm-230000882.html
ONTY
@
$2.83
HOLD no good options at this time
History:
Cost basis
$5.00
per share.
Premiums collected:
2.20
per share
44%
Return in 25 months
$10,000 would have generated
$4400.00
actual trades:
03/18/2013 Sell To Open ONTY Jun13 5 Call $0.05
11/19/2012 Sell To Open
ONTY Jan13 6 Call $0.55
05/21/2012 Sell To Open
ONTY Nov12 7 Call $0.05
03/20/2012 Sell To Open ONTY May12 6 Call $0.05
03/16/2012 Buy ONTY

Option Assignment
$5.00
03/16/2012 Buy To Close
ONTY Mar12 $5 Put
02/21/2012
Sell To Open
ONTY Mar12 $5 Put $0.70

02/19/2012 Buy To Close
EXPIRED ONTY FEB12 $5 PUT
01/30/2012 Sell To Open
ONTY Feb12 5 Put $0.50
01/22/2012 Buy To Close
EXPIRED ONTY JAN12 $5 PUT
01/09/2012 Sell To Open
ONTY Jan12 5 Put $0.30
Oncothyreon Inc.(ON
TY), a clinical

stage biopharmaceutical company, focuses
on the development of therapeutic products for the treatment of cancer. Its
primary product candidate, Stimuvax is in Phase III clinical trials for the treatment
of non

small cell lung cancer. The co
mpany also develops PX

866, a small
molecule that is in Phase II trials. In addition, it engages in the preclinical
development of ONT

10, a cancer vaccine. The company operates in Canada,
the United States, Barbados, and Europe. Oncothyreon Inc. was found
ed in 1985
and is headquartered in Seattle, Washington.
Oncothyreon Inc
2601 Fourth Avenue
Suite 500
Seattle, WA 98121
Phone: 206

801

2100
Fax: 206

801

2101
Website:
http://www.oncothyreon.com
News:
PAAS
@ $15.13
Hold
there are no good options at this time.
History:
Cost basis
$36.00
per share.
Premiums collected:
$3.50
per share
Dividends
.63c
Total:
$4.13
11.04%
Return in 36 months
$10,000 would have generated $1104.00
actual trades:
12/11/2013 PAAS

PAAS QUALIFIED DIVIDEND .125
09/06/2013 PAAS

PAAS QUALIFIED DIVIDEND .125
06/19/2013 PAAS

PAAS QUALIFIED DIVIDEND .125
03/19/2013 PAAS

PAAS QUALIFIED DIVIDEND .125
12/04/2012 PAAS

PAAS QUALIFIED DIVIDEND .125
09/24/2012 Sell To O
pen PAAS Jan13 40 Call $0.05

01/30/2012Sell To Open PAAS Jul12 36 Call $0.20
12/06/2011 PAAS

PAAS QUALIFIED DIVIDEND $.025
10/24/2011 Sell To Open
PAAS Jan12 36 Call $0.40
10/22/2011 Buy To Close
EXPIRED PAAS Oct11 36 Call
09/08/2011 PAAS

PAAS QUALI
FIED DIVIDEND $.025
06/20/2011 Sell To Open
PAAS Oct11 36 Call $0.80
06/19/2011 Buy To Close
EXPIRED PAAS JUN11 36 CALL
06/16/2011 PAAS QUALIFIED DIVIDEND $.025
05/23/2011 Sell To Open
PAAS Jun11 36 Call $0.50
05/20/2011 Buy PAAS

Option Assignment
$3
6.00
05/20/2011 Buy To Close
PAAS May11 36 Put $0.00
04/18/2011 Sell To Open
PAAS May11 36 Put $1.55
Pan American Silver Corp. engages in the exploration, development, extraction,
processing, production, refining, reclamation, and operation of silver p
roperties. The
company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had
seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was
founded in 1979 and is headquartered in Vancouver, Canada.
Pa
n American Silver Corp.
625 Howe Street
Suite 1500
Vancouver, BC V6C 2T6
Phone: 604

684

1175
Fax: 604

684

0147
Website:
http://www.panamericansilver.com
News:
PAY
@ $28.76
Hold:
no good options at this time.
History:
Cost basis
$43.00
per share.
Premiums collected:
$3.36
per share
7.63%
Return
in 33 months
$10,000 would have generated
$758.00
actual trades:
10/22/2012 Sell To Open
PAY Jan13 44 Call $0.10
06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35
05/21/2012 Sell To Open
PAY Jun12 50 Call $1.00
04/16/2012 Sell To Open
PAY May12 57.5 C
all $1.02
04/16/2012 Buy To Close
PAY Apr12 49 Call

$5.36
01/23/2012 Sell To Open
PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close
EXPIRED PAY JAN12 49 CALL
10/31/2011 Sell To Open
PAY Jan12 49 Call $0.90
10/31/2011 Buy To Close
PAY Jan12 46 Call

$1.9
0
10/24/2011 Sell To Open PAY Jan12 46 Call $1.10
10/22/2011 Buy To Close
EXPIRED PAY Oct11 42 Call
08/23/2011 Sell To Open
PAY Oct11 42 Call $0.60
08/21/2011 Buy To Close
EXPIRED PAY AUG11 46
Call
07/19/2011 Sell To Open
PAY Aug11 46 Call $1.05
07/17/
2011 Buy To Close
EXPIRED PAY JUL11 44 Call
06/20/2011 Sell To Open
PAY Jul11 44 Call $0.75
06/17/2011 Buy To Close
PAY Jun11 43 Put $0.00
06/17/2011 Buy PAY

Option Assignment $43.00
05/23/2011 Sell To Open
PAY Jun11 43 Put $1.70
VeriFone Systems, Inc.
designs, markets, and services electronic payment solutions that
enable secure electronic payments among consumers, merchants, and financial institutions
worldwide. The company provides countertop electronic payment systems that accept
magnetic, smart car
d, and contactless/radio frequency identification cards; and support
credit, debit, check, electronic benefits transfer, and various pre

paid products, as well as
offers wireless system solutions. The company also provides products for the point of sale
ap
plications, which include displays, user

friendly interfaces, electronic cash registers
(ECR) interfaces, durable key pads, and signature capture functionality; and
contactless/near field communication (NFC) payment solutions for consumer

activated
transac
tions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it
offers various products for petroleum companies, such as integrated electronic payment
systems that combine card processing, fuel dispensing, and ECR functions, as well as
secure payment systems for integration with petroleum pump controllers and systems.
Further, the company provides server

based transaction products; secure payment
hardware and software integration modules; and VeriShield Protect, a solution that encrypts
and protects consumer card data. Additionally, it offers client services, including payment
system consulting, deployment, on

site and telephone

based installation and training, help
desk support, repairs, replacement of impaired system solutions, asset t
racking, and
reporting; and project management services. The company serves financial institutions,
payment processors, petroleum companies, retailers, government organizations, and
healthcare companies, as well as independent sales organizations. The comp
any was
formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems,
Inc. in May 2010. The company is headquartered in San Jose, California.
VeriFone Systems, Inc
2099 Gateway Place
Suite 600
San Jose, CA 95110
Phone: 408

232

7800
Fax: 408

232

7811
Website:
http://www.verifone.com
News:
PRKR
@ $4.84
Parkervision Inc.
Hold
PRKR March 2014 $6 Call still cooking

History:
Cost basis
$5.00
per share.
Premiums collected:
$.60
per share
12%
Retu
rn in 4 months
$10,000 would have generated $450.00
actual trades:
12/23/2013 Sell To Open PRKR Mar14 6 Call $0.15
11/15/2013 Buy PRKR

Stock Assignment $5.00
10/21/2013 Sell To Open PRKR Nov13 5 Put $0.45
ParkerVision, Inc. designs, develops, and mar
kets proprietary radio frequency
(RF) technologies and products for use in semiconductor circuits for wireless
communication products in the United States. It offers its technologies for
processing RF waveforms in wireless applications. Its technology appl
ies to
both transmit and receive functions of a radio transceiver. The transmit portion
of the technology, Direct2Power, enables the transformation of a baseband data
signal to an RF carrier waveform at the desired power output level in a single
unified op
eration. The receiver portion of the technology, Direct2Data, enables
the direct conversion of an RF carrier to a baseband data signal. The company
also provides engineering consulting and design services to its customers to
assist them in developing proto
types and/or products incorporating its
technologies. It focuses on incorporating its technologies into mobile handsets
for 3G and 4G cellular networks, as well as to other wireless products that are
related to networks serving mobile handsets, such as tab
lets, data cards,
femtocells, machine

to

machine, and embedded applications. The companys technology is also used in non

cellular radio applications comprising military
radios and cable modems. ParkerVision, Inc. was founded in 1989 and is
headquartered i
n Jacksonville, Florida. TRGT
@ $4.76
Hold
Take no action
There is no good option interest at this time.
History:
Cost basis
$12.50
per share.
Premiums collected:
$2.25
per share
18%
Return in 28 months
$10,000 would have generated $1800.00

a
ctual trades:
02/21/2012 Sell To Open
TRGT May12 15 Call $0.25
11/28/2011 Sell To Open
TRGT Feb12 15 Call $0.40
11/18/2011 Buy To Close
TRGT Nov11 12.5 Put
11/18/2011 Buy TRGT

Option Assignment $12.50
10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $
1.60
Targacept, Inc., a biopharmaceutical company, engages in the design,
discovery, and development of novel Neuronal Nicotinic Receptors (NNR)
Therapeutics for the treatment of diseases and disorders of the nervous system.
Its lead program, TC

5214, a n
icotinic channel modulator, is in Phase 3 clinical
trials as an adjunct treatment for major depressive disorder (MDD) and in
Phase 2b clinical trial for switch monotherapy in patients with MDD. The
company s novel small molecule product candidates under Ph
ase 2 clinical
development include TC

5619 for treating negative symptoms and cognitive
dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and
Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s
disease; AZD144
6 as a treatment for Alzheimer s disease; and TC

6987 for the
treatment of inflammatory disorders, including asthma and Type 2 diabetes. It
has a collaborative research and license agreement with AstraZeneca AB for the
development and commercialization of
AZD3480, TC

5214, and TC

5619; and a
product development and commercialization agreement with SmithKline
Beecham Corporation to discover, develop, and market product candidates that
selectively target specified NNR subtypes in specified therapeutic focus a
reas.
The company was founded in 1997 and is based in Winston

Salem, North
Carolina.
Targacept, Inc.
200 East First Street
Suite 300
Winston

Salem, NC 27101

4165
Phone: 336

480

2100
Fax: 336

480

2107
Website:
http://www.targacept.com
News:
Earnings report in February
VJET
@ $35.08
Voxeljet AG (VJET)
Sell To Open VJET May 14 $60 Call @ Market
currently .35c bid / .50c time
+.06%
return in 84 days
History:
Cost basis
$55.00
per share

Premiums collected:
$
4.35
per share
7.9%
Return in 3 months
$10,000 would have generated $790.00
actual trades:
12/23/2013 Sell To Open VJET Feb14 60 Call$0.35
11/18/2013 Sell To Open VJET Dec13 $55 Put $4.00
voxeljet AG provides three

dimensional (3D) printers and on

deman
d parts services. Its 3D
printers employ a powder binding additive manufacturing technology to produce parts using
various material sets. The company operates in two segments, Systems and Services. The
Systems segment focuses on the production, development
, and sale of 3D printers. It also
offers consumables, such as particulate materials and proprietary chemical binding agents,
maintenance contracts, and spare parts. The Services segment prints on

demand parts at
its service center through its 3D printers,
material sets, and in

house finishing capabilities.
The company provides its 3D printers and on

demand parts services to industrial and
commercial customers in automotive, aerospace, film and entertainment, art and
architecture, engineering, and consumer
product end markets in Europe, the Middle East,
Africa, the Asia Pacific, and the Americas. voxeljet AG was founded in 1999 and is
headquartered in Friedberg, Germany
Voxeljet AG
Paul

Lenz Strasse 1b
Friedberg, 86316
Germany
Phone: 49 821 7483 100
Fax:
49 821 7483 111
Website:http://www.voxeljet.de
News:
ZIOP
@ $4.40
ZIOPHARM Oncology, Inc
.
HOLD
ZIOP April14 $6 Call
still cooking
History:
Cost basis
$3.00
per share.
Premiums collected:
$.60
per share
20%
Return in 11 months
$10,000 would have generated $833.00
actual trades:
01/21/2014 Sell To Open ZIOP Apr14 $6 Call $0.35
04/22/2013 Sell To Open ZIOP Jan14 $5 Call $0.05
04/19/2013 Buy ZIOP

Stock Assignment $3.00

03/18/2013 Sell To Open ZIOP Apr1
3 3 Put $0.20
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on
the development and commercialization of new cancer therapies. Its lead
candidate, Palifosfamide (ZIO

201), a potent bi

functional DNA alkylating
agent, is under Phase III tri
al for the treatment of first

line metastatic soft
tissue sarcoma, as well as in a pivotal Phase III trial for first

line
metastatic small cell lung cancer. The companys olio of clinical

stage product candidates also include IL

12 DNA, which is being
tested
in a Phase 2 study using synthetic biology to enable controlled, local
delivery of therapeutic interleukin

12; Indibulin (ZIO

301), a novel, tubulin
binding agent under Phase I/II trial in metastatic breast cancer; and
Darinaparsin (ZIO

101), a nov
el mitochondrial

and hedgehog

targeted
agent. In addition, its portfolio comprises various research

stage
candidates. The companys NA therapeutics are being developed in
partnership with Intrexon Corporation through a synthetic biology
platform that all
ows for targeted, controlled production of therapies in
humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was
founded in 2003 and is headquartered in New York, New York with
operations center located in Boston, Massachusetts.
ZIOPHARM Oncol
ogy, Inc.
1180 Avenue of the Americas
20th Floor
New York, NY 10036
Phone: 646

214

0700
Fax: 646

214

0711
Website:
http://www.ziopharm.com
News:
seekingalpha.com/article/1899291

ziopharm

finally

a

winner

in

the

war

on

cancer?
ZNGA
@ $5.00
Hold
Take no action
There is no good option interest at this time.
History:
Cost basis
$14.00
per share.
Premiums collected:
$2.05
per share
14.64%
Return in 24 months
$10,000 would have generated
$1464.00
actual trades:

03/19/2012 Sell To Open ZNGA Apr 2012 $16 Call $0.20
03/18/2012 Buy To Close EXPIRED ZNGA MAR12 $15 CALL
02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40
02/17/2012 Buy
ZNGA

Option Assignment $14.00
02/17/2012 Buy To Close ZNGA Feb12 $14 Put
02/06/
2012 Sell To Open ZNGA Feb12 14 Put $1.55
Zynga Inc. develops, markets, and operates online social games as live
services on the Internet, social networking sites, and mobile platforms.
The company offers its online social games under the CityVille, Zyng
a
Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with
Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends,
Slingo, and Dream Heights names. Its games are available on various
platforms, including Facebook and other social network
s, as well as
mobile platforms, such as Apple iOS and Google Android worldwide. The
company was formerly known as Zynga Game Network Inc. and
changed its name to Zynga Inc. in November 2010. Zynga Inc. was
founded in 2007 and is headquartered in San Franci
sco, California.
Zynga, Inc.
699 Eighth Street
San Francisco, CA 94103
Phone: 855

449

9642
Fax: 302

636

5454
Website:
http://www.zynga.com
News: Quote of the Month:

The Stock Market is designed to transfer money from the Active
to the Patient “
~
Warren Buffet
Until Next Time
Brad Lee
The Options Oracle
https://theoptionsoracle.com/
The place for safer Investments

Established 23 February 2009
Ask The Oracle Webinar Sunday 8 pm EST
to explain this newsletter, or other questions you might have.
Here is the link
https://secure.join.me/BradLeeOptions
There is no preregistration. Please use the phone option for audio
Summary of Trades:
Cash Covered Puts Sell T
o Open INSM March 2014 $15.
Put @ Market Sell To Open QCOR March 2014 $70
Put @ Market Sell To Open SCTY March 2014 $75.
Put @ Market Stock Covered Calls
(do not buy into these positions)
Sell To Open CLSN March 2014 $4
Call @ Market Sell To Open VJ
ET May 14 $60 Call @ Market
Called away:
02/21/2014 MYGN Stock Assignment
$27.00
20.4%
Return in 3 months
02/21/2014 Sell MYGN Stock Assignment$27.00
01/21/2014 Sell To Open MYGN Feb14 $27 Call $0.35
12/23/2013 Sell To Open MYGN Jan14 $27 Call $0.85
1
2/20/2013 Buy MYGN

Stock Assignment $25.00
11/18/2013 Sell To Open MYGN Dec13 $25 Put $1.90
Past performance click here
https://theoptionsoracle.com/past-performances/
Company News
New toll free number:
1

866

466

4617
Feel free to con
tact me personally!
Got a question or concern? Want to
learn my philosophy and why it pays
so well and consistently? Go to
“contact us”
https://theoptionsoracle.com/contacting-us/
and schedule a
consultation.
Military discounts are here!
Thank you for your service!
Refer a Friend
The greatest compliment you can give
me is to share me with your friends.
Disclosure: These are my actual trades.
I am not telling you what to do, I am s
howing you
what I am doing.
Your subscription fee may be 100% TAX
DEDUCTIBLE if used for educational

business/investment purposes.
Check with
your Licensed Professional adviser
In Loving Memory
Ronald E. Lee 1939-2013

Company News
Auto
Trading is now active!
Don’t want to be bothered doing the trades?
Auto

trading is for you. Your account will
automatically do whatever I do.
You are still in control, you set the limits
either a dollar amount or a percentage.
Go to the main site, the Au
to

trade link is on
the site
https://theoptionsoracle.com/auto-trading/
We will be doing a webinar Sunday 8
pm est to explain this newsletter.
Here is the link
https://secure.join.me/BradLeeOptions

Disclosure:

These are my actual trades. Your subscription fee may be 100% TAX
DEDUCTIBLE if used for educational business/investment purposes.
Check with your Licensed Professional adviser Options involve risk and are not suitable for all
investors. Prior to trading options, you must be approved for options trading and read the
Characteristics and Risks of Standardized Options. Copies of t his document may also be obtained
from your broker, from any exchange on which options are traded, by placing an order online, or
by contacting the Options Clearing Corporation directly at 1 N. Wacker Dr., Suite 500, Chicago, IL
60606. (1-888-678-4667). Brad Lee AKA “The Options Oracle” and
“The Money Medic” is an individual investor who does not manage money for any
financial institution. You are purchasing the list of stocks that he uses to select options
contracts he feels will return him the highest, safest profits. Brad is not a broker, or
financial adviser. He is a remarkable investor who has developed a successful strategy for himself, and is willing to share some of his magic with you. We urge you to paper trade
these picks and learn how to develop a strategy that is appropriate for you. Thank
You. We make no recommendations on investment and we do not provide financial,
tax or legal advice. Content and tools are  provided for educational and informational
purposes only.

Disclaimer:
Trading or investment in stocks, futures & options, and
commodity are subject to potential market risks. You can
use our materials or recommendations for educational
purposes, this is not intended as Trading or Investment
advice. We are not financial advisers. We c
annot provide any advice as to whether or not options or our trading
ideas are suitable investments for your particular
financial situation. We are in the business of publishing
our trade ideas for market analysis only. We highly
recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.
Legal Disclaimer: we do not exist to render and do not
give legal, tax, economic or investment advice and
disclaims all liability for the actions or inaction taken or
not as a result of communications from or to its
members, officers, directors, employees and contractors.
Each individual should consult his/her own counsel,
accountant and other advisors as to legal, tax, economic,
investment and related matters conc
erning any type of investments.
This email and any files transmitted with it are solely
intended for the use of the addressee(s) and may
contain information that is confidential and privileged. If
you receive this email in error, please advise us by return
email immediately. Please also disregard the contents of
the email, delete it and destroy any copies immediately.